Sai Life Sciences
922.30
-0.80(-0.09%)
Market Cap₹19,299.10 Cr
PE Ratio79.42
IndustryHealthcare
Company Performance:
1D-0.09%
1M+6.47%
6M+27.90%
1Y+20.62%
5Y+20.62%
View Company Insightsright
More news about Sai Life Sciences
26Aug 25
Goldman Sachs and Societe Generale Acquire Significant Stakes in Sai Life Sciences
Goldman Sachs and Societe Generale have made substantial investments in Sai Life Sciences through open market transactions. Goldman Sachs acquired 1.10 million shares, while Societe Generale purchased 1.40 million shares of the Indian pharmaceutical company. These investments by major global financial institutions could be viewed as a vote of confidence in Sai Life Sciences' business model and future prospects.
25Aug 25
TPG Asia to Exit Sai Life Sciences with ₹2,500 Crore Block Deal
TPG Asia plans to divest its entire 14.72% stake in Sai Life Sciences through a block deal valued at approximately ₹2,500 crore. The sale involves 3.07 crore shares at a floor price of ₹860 per share, a 5% discount to the last closing price. Sai Life Sciences reported strong Q3 results with a profit of ₹60 crore, 77% increase in revenue to ₹496 crore, and EBITDA margin expansion to 25%. The company projects 15-20% annual revenue growth over the next 3-5 years.
08Aug 25
Sai Life Sciences Reappoints Krishnamraju Kanumuri as MD & CEO, Reports Strong Q1 FY2026 Results
Sai Life Sciences has reappointed Krishnamraju Kanumuri as Managing Director and CEO for a five-year term from September 1, 2025, to August 31, 2030, subject to shareholder approval. The company reported robust Q1 FY2026 financial results with revenue from operations increasing by 77.50% year-over-year to ₹4,964.19 million. Profit After Tax reached ₹604.55 million, marking a return to profitability. Basic EPS for the quarter was ₹2.90. The company's 26th Annual General Meeting is scheduled for September 11, 2025.
07Aug 25
Sai Life Sciences Reports Strong Q1 Performance, Reappoints CEO
Sai Life Sciences Limited, a CRDMO company, reported robust Q1 financial results. Consolidated revenue increased 77.47% to Rs. 4,964.19 crore. The company turned a profit, with PAT at Rs. 604.55 crore compared to a loss in the previous year. Standalone revenue grew 82.64% to Rs. 4,830.38 crore. The Board approved the reappointment of Mr. Krishnamraju Kanumuri as Managing Director & CEO for another five-year term. The company's 26th AGM is scheduled for September 11, 2025.
20Jun 25
TPG Offloads Rs 1,505 Crore Stake in Sai Life Sciences, Stock Rallies 5%
Private equity firm TPG sold over 2 crore shares of Sai Life Sciences at Rs 722.00 per share, totaling approximately Rs 1,505.00 crore. Key buyers included Norges Bank and Indian mutual funds such as Nippon India, Invesco, and Aditya Birla Sun Life. The stock rallied 5% following the transaction, closing at Rs 765.85 on the BSE. Sai Life Sciences is a contract research, development, and manufacturing organization serving the pharmaceutical industry.
20Jun 25
SAI Life Sciences Expands Capacity with Bidar Unit IV Phase Two Launch
Sai Life Sciences, a leading CRDMO, has commenced commercial operations for phase two at its Bidar Unit IV facility. This expansion has increased the company's total production capacity to 640 KL, significantly enhancing its ability to meet growing demand in the pharmaceutical and biotechnology sectors. The expansion positions Sai Life Sciences for strategic growth, potentially allowing it to handle larger and more complex projects.
20Jun 25
Sai Life Sciences: Major Block Deal Sees 10% Equity Change Hands
Sai Life Sciences experienced a significant block deal involving 10% of its equity. TPG Asia, a major stakeholder, is believed to be selling about 6% of its holding (12.5 million shares) at ₹710.00 per share, totaling approximately $102 million. This would reduce TPG Asia's stake from 24.73% to around 18.73%. Despite this, Sai Life Sciences projects a 15-20% revenue CAGR over the next 3-5 years and aims to improve margins from 24% to 30%.
19Jun 25
TPG Asia to Offload 6% Stake in Sai Life Sciences for ₹887.5 Crore
TPG Asia plans to divest a 6% stake in Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization. The block deal involves 12.5 million shares priced at ₹710.00 each, a 2.5% discount to the market price. The total deal value is approximately ₹887.50 crore ($102 million). A 60-day lock-in period will be imposed on TPG Asia post-transaction.
14May 25
Sai Life Sciences Sets Ambitious Growth Targets, Eyes Margin Expansion
Sai Life Sciences, a leading CRDMO, has announced plans for significant expansion. The company aims for a 15-20% CAGR in revenues over the next 3-5 years and targets to increase profit margins from 24% to 30%. In Q4FY25, the company reported revenue of ₹579.00 crore with a 27.20% profit margin. Sai Life Sciences sees growth opportunities in the global trend of diversifying pharmaceutical supply chains away from China, particularly due to pricing uncertainties in the US market.
04Apr 25
Sai Life Sciences Expands Research Capabilities with New Peptide Research Center in India
Sai Life Sciences has established a new Peptide Research Center at its R&D Campus in Hyderabad, India. The facility features state-of-the-art technology for complex peptide synthesis and conjugation, including automation and robotics. This expansion aims to meet the growing demand for peptide-based therapeutics and reinforces the company's position in advancing next-generation drugs. The center will offer specialized services in peptide synthesis, discovery, and advanced modalities, integrated with Sai Life Sciences' existing end-to-end discovery services.
03Apr 25
Sai Life Sciences Expands Capabilities with New Peptide Research Center in India
Sai Life Sciences has established a new Peptide Research Center at its R&D Campus in Hyderabad, India. The state-of-the-art facility integrates automation, advanced liquid handling, robotics, and high-throughput systems to enhance peptide research and development. It offers specialized services in peptide synthesis, discovery, and advanced modalities, supporting innovator pharma and biotech companies. The center is integrated with Sai Life Sciences' existing end-to-end discovery services, aiming to accelerate timelines for peptide-based drug development.
Sai Life Sciences
922.30
-0.80
(-0.09%)
1 Year Returns:+20.62%
Industry Peers
Sun Pharmaceutical
1,685.90
(-0.24%)
Divis Laboratories
6,883.50
(+1.16%)
Cipla
1,501.50
(-0.12%)
Torrent Pharmaceuticals
3,553.40
(-0.60%)
Dr Reddys Laboratories
1,205.20
(+0.43%)
Mankind Pharma
2,309.10
(-2.55%)
Zydus Life Science
936.70
(-3.60%)
Lupin
1,955.50
(-2.08%)
Alkem Laboratories
5,643.50
(-0.36%)
Aurobindo Pharma
1,140.60
(-0.74%)